Sign up to save your podcasts
Or
Share ACC CardiaCast: Emerging Data in SGLT2 Inhibitors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACC CardiaCast: Emerging Data in SGLT2 Inhibitors
This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.
View all episodes
By American College of Cardiology
4.4
3737 ratings
This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.
More shows like ACC CardiaCast
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
498 Listeners
JACC This Week
169 Listeners
This Week in Cardiology
885 Listeners
Mayo Clinic Talks
289 Listeners
The Curbsiders Internal Medicine Podcast
3,344 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
140 Listeners
Core IM | Internal Medicine Podcast
1,156 Listeners
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
61 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
90 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Run the List
253 Listeners
Cardionerds: A Cardiology Podcast
431 Listeners